Preparing Emerging Biotechs for the Best Deals


Albert Sokol predicted that the new tax law’s profits repatriation provisions and lower corporate rates mean “there will be more bio-side cash” for acquisitions and formal alliances that « sometimes energize fallow assets. » Given such innovation, he continued, « There’s no longer just one way to do stuff; there’s no longer merely the classic venture capitalists. There are now many corporate venture capital arms of pharma.”